Double lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome.

Autor: Fakhro M; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden. mohammed.fakhro@med.lu.se., Broberg E; Department of Thoracic Intensive Care and Anesthesia, Skåne University Hospital, Lund University, Lund, Sweden., Algotsson L; Department of Thoracic Intensive Care and Anesthesia, Skåne University Hospital, Lund University, Lund, Sweden., Hansson L; Department of Pulmonary Medicine, Skåne University Hospital, Lund University, Lund, Sweden., Koul B; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden., Gustafsson R; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden., Wierup P; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden., Ingemansson R; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden., Lindstedt S; Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden.
Jazyk: angličtina
Zdroj: Journal of cardiothoracic surgery [J Cardiothorac Surg] 2017 Nov 25; Vol. 12 (1), pp. 100. Date of Electronic Publication: 2017 Nov 25.
DOI: 10.1186/s13019-017-0666-5
Abstrakt: Background: Survival after lung transplantation (LTx) is often limited by bronchiolitis obliterans syndrome (BOS).
Method: Survey of 278 recipients who underwent LTx. The endpoint used was BOS (BOS grade ≥ 2), death or Re-lung transplantation (Re-LTx) assessed by competing risk regression analyses.
Results: The incidence of BOS grade ≥ 2 among double LTx (DLTx) recipients was 16 ± 3% at 5 years, 30 ± 4% at 10 years, and 37 ± 5% at 20 years, compared to single LTx (SLTx) recipients whose corresponding incidence of BOS grade ≥ 2 was 11 ± 3%, 20 ± 4%, and 24 ± 5% at 5, 10, and 20 years, respectively (p > 0. 05). The incidence of BOS grade ≥ 2 by major indications ranked in descending order: other, PF, CF, COPD, PH and AAT1 (p < 0. 05). The mortality rate by major indication ranked in descending order: COPD, PH, AAT1, PF, Other and CF (p < 0. 05).
Conclusion: No differences were seen in the incidence of BOS grade ≥ 2 regarding type of transplant, however, DLTx recipients showed a better chance of survival despite developing BOS compared to SLTx recipients. The highest incidence of BOS was seen among CF, PF, COPD, PH, and AAT1 recipients in descending order, however, CF and PF recipients showed a better chance of survival despite developing BOS compared to COPD, PH, and AAT1 recipients.
Databáze: MEDLINE
Externí odkaz: